Activation of the NLRP3 inflammasome induces maturation of IL-1beta and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active beta-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1beta and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1beta levels by 60% and IL-18 by 70% at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1beta release and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1beta release by 84% and 36%. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1beta precursor. Steady-state levels of phosphorylated NF-kappaB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1beta content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism in OLT1177-treated mice challenged with LPS. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.
- Marchetti, C.
- Swartzwelter, B.
- Gamboni, F.
- Neff, C. P.
- Richter, K.
- Azam, T.
- Carta, S.
- Tengesdal, I.
- Nemkov, T.
- D'Alessandro, A.
- Henry, C.
- Jones, G. S.
- Goodrich, S. A.
- St Laurent, J. P.
- Jones, T. M.
- Scribner, C. L.
- Barrow, R. B.
- Altman, R. D.
- Skouras, D. B.
- Gattorno, M.
- Grau, V.
- Janciauskiene, S.
- Rubartelli, A.
- Joosten, L. A. B.
- Dinarello, C. A.
Keywords
- Animals
- Anti-Inflammatory Agents/chemistry/*pharmacology/therapeutic use
- Caspase 1/metabolism
- Cells, Cultured
- Humans
- Inflammasomes/*antagonists & inhibitors
- Inflammation/chemically induced/immunology/*prevention & control
- Interleukin-18/metabolism
- Interleukin-1beta/metabolism
- Lipopolysaccharides/toxicity
- Macrophages/*drug effects/metabolism/pathology
- Male
- Mice
- Mice, Inbred C57BL
- NLR Family, Pyrin Domain-Containing 3 Protein/genetics/*metabolism
- Nitriles/chemistry/*pharmacology/therapeutic use
- *nlrp3
- *caspase-1
- *interleukin-1
- Advisory Board, is co-Chief Scientific Officer, and receives compensation.
- L.A.B.J. serves on Olatec's Scientific Advisory Board and receives compensation.
- J.P.S.L. has equity in Olatec. D.B.S. serves as Chairman and Chief Executive
- Officer of Olatec, R.B.B. serves as Chief Operating Officer of Olatec, and C.L.S.
- and R.D.A. serve on Olatec's Scientific Advisory Board.